Back

FDA approves Eli Lilly's Onswik as stock rises 2.85%

Verifying
  • FDA approved Eli Lilly's Onswik for adults with type 2 diabetes.
  • Eli Lilly shares rose 2.85% to $1,183.76.
  • Onswik adds a once-weekly insulin treatment to Eli Lilly's diabetes portfolio.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.